Critical Analyzers, Laboratory (FSS-66-III)

The Department of Veterans Affairs Veterans Health Administration is operating a Master GSA Schedule (Critical Analyzers, Laboratory) established on October 1, 2003, for clinical laboratory analyzers covering chemistry, coagulation, hematology, immunochemistry, microbiology, and urinalysis equipment and consumables; ordering closed on September 1, 2024, making this vehicle inactive for new vendor entry.

With 10,000 total task orders awarded over twenty-two years and $5.75 billion in combined potential value, this vehicle shows sustained federal demand for laboratory instrumentation. However, ordering activity has decelerated markedly: the most recent task-order award was September 1, 2026, yet 2026 saw only 365 orders compared to 955 in 2025 and 973 in 2024, reflecting the closure of the ordering period. Obligated dollars total $3.77 billion, representing 66 percent of combined potential value. The original solicitation (RFP-797-FSS-03-0001-R1) issued in July 2008 as a standing, open-and-continuous multiple-award FSS contract with an advertised due date of December 30, 2026 for new offers; that deadline has passed.

Beckman Coulter, Inc. dominates the vehicle's activity, holding 4,920 orders and $1.25 billion in combined potential value—roughly 22 percent of all orders. Siemens Healthcare Diagnostics Inc., Roche Diagnostics Corporation, and Ortho-Clinical Diagnostics, Inc. follow with substantial footprints. By dollar value, Abbott Laboratories Inc. ranks second with $1.06 billion potential across 985 orders, indicating higher per-order values than Ortho-Clinical despite fewer awards. The five largest primes by value control 77 percent of combined potential value, signaling meaningful concentration; a broader field of 26 distinct prime contractors participates, though most are substantially smaller.

Customer concentration remains high: the Department of Veterans Affairs Veterans Integrated Service Networks collectively place roughly 71 percent of all orders across multiple regional networks, with VISN 16, VISN 10, VISN 23, and VISN 12 each placing substantial volumes. The Department of Health and Human Services Indian Health Service is the second-largest customer with 2,037 orders and $176.2 million in combined potential value.

All task orders carry "No Set-Aside Used" designations; this is an unrestricted vehicle. Contracts are fixed-price indefinite delivery-indefinite quantity awards with Economic Price Adjustment provisions, with performance periods of five years from award date and optional extensions exercisable at Government discretion.

Recent awards (July and June 2026) range from small orders of $2,000–$50,000 to significant BPA calls exceeding $750,000–$4.9 million, reflecting the mix of individual facility cost-per-test and reagent orders alongside regional automation-line contracts. Place of performance spans F.O.B. Destination within the contiguous 48 states, District of Columbia, and optional service areas in Alaska, Hawaii, Puerto Rico, and worldwide locations. All equipment must be FDA-approved current production models, comply with CLIA and Clinical Laboratory Standards Institute standards, interface with the VistA laboratory information system, and achieve 90 percent effectiveness within 30 days post-installation.

Since the ordering period closed in September 2024, this vehicle is no longer available for new contract awards or vendor entry, making pursuit non-viable for prospective bidders.

Clinical Chemistry Analyzers